Aethlon Medical reports two-fold Long COVID signal

• Aethlon Medical reported peer-reviewed research linking Long COVID samples to roughly two-fold higher mannose-positive extracellular vesicles.
• AEMD shares were down at $0.89 following the announcement.
• The company said the findings support future Hemopurifier studies, while its main resources remain focused on oncology.

Aethlon Medical (NASDAQ:AEMD) announced peer-reviewed Long COVID research showing roughly two-fold higher mannose-positive extracellular vesicles in patient samples.

The release moves the company’s November 2025 preclinical findings from preprint form into a peer-reviewed article in the International Journal of Molecular Sciences.

“The publication of this study contributes to the scientific understanding of the biological mechanisms underlying Long COVID,” said Aethlon Medical Chief Executive Officer and Chief Financial Officer Jim Frakes.

The study also reported GNA resin capture of disease-associated small EVs, reduction of seven immune-related microRNAs, and pathway signals involving JAK-STAT, VEGF, PI3K, and estrogen signaling.

Following the announcement, Aethlon Medical's share price was down at $0.89.

Aethlon said its main resources remain focused on its Australian oncology clinical trial, while the Long COVID findings may support future preclinical and clinical studies.

The Hemopurifier is a clinical-stage immunotherapeutic device designed for cancer, life-threatening viral infections, and organ transplantation.